bluebird bio Announces Transition of Chief Strategy Officer Jeffrey T. Walsh
October 23 2019 - 4:30PM
Business Wire
bluebird bio, Inc. (Nasdaq: BLUE) today announced that Jeffrey
T. Walsh, chief strategy officer, has decided to transition from
his current role effective January 6, 2020.
“On behalf of bluebird, we are grateful for all that Jeff has
accomplished over the past eight years in a variety of roles to
advance our growth and operational strategies, and for his deep
commitment to our patients, people and culture,” said Nick Leschly,
chief bluebird. “Jeff has left his mark on all of us as a valued
leader, coach, and mentor and, personally, I will miss his
partnership. His enormous contributions to bluebird have a very
special place in our history and will continue to guide us well
into the future.”
“My time with bluebird has been one of the most rewarding
experiences of my career,” said Jeff Walsh. “The opportunity to
help lead the growth of our company from a fledgling start-up to a
leader in gene therapy that is now ready to deliver transformative
therapies to patients, is not something that everyone has the great
fortune to do. While this was a very difficult decision, I’m
incredibly proud of our accomplishments and this team has shown me
what it means to break through barriers in a serious way to help
patients and each other. I’ll always fly high as a proud member of
the bluebird extended family, and fondly remember all of the fun we
had along the way as we never took ourselves too seriously.”
Jeff has not only built a strong foundation for bluebird’s
overall growth strategy but also leaves an experienced and
passionate team. Both Chip Baird, chief financial officer, and
Joanne Smith-Farrell, chief business officer, will assume broader
corporate development and strategic responsibilities as bluebird
continues to deliver on its mission for patients.
About bluebird bio, Inc. bluebird bio is pioneering gene
therapy with purpose. From our Cambridge, Mass., headquarters,
we’re developing gene therapies for severe genetic diseases and
cancer, with the goal that people facing potentially fatal
conditions with limited treatment options can live their lives
fully. Beyond our labs, we’re working to positively disrupt the
healthcare system to create access, transparency and education so
that gene therapy can become available to all those who can
benefit.
bluebird bio is a human company powered by human stories. We’re
putting our care and expertise to work across a spectrum of
disorders by researching cerebral adrenoleukodystrophy, sickle cell
disease, transfusion-dependent β-thalassemia and multiple myeloma
using three gene therapy technologies: gene addition, cell therapy
and (megaTAL-enabled) gene editing.
bluebird bio has additional nests in Seattle, Wash.; Durham,
N.C.; and Zug, Switzerland. For more information, visit
bluebirdbio.com.
Follow bluebird bio on social media: @bluebirdbio,
LinkedIn, Instagram and YouTube.
bluebird bio is a trademark of bluebird bio, Inc.
Forward-Looking Statements This release contains
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995, including statements
regarding the advancement of, and anticipated development and
commercialization plans for, the Company’s product and product
candidates. Any forward-looking statements are based on
management’s current expectations of future events and are subject
to a number of risks and uncertainties that could cause actual
results to differ materially and adversely from those set forth in
or implied by such forward-looking statements. These risks and
uncertainties include, but are not limited to, the risks that
results from our prior and ongoing clinical trials of our product
candidates will not continue or be repeated in our ongoing or
planned clinical trials; risks that the current or planned clinical
trials of our product candidates will be insufficient to support
future regulatory submissions or to support marketing approval in
the U.S. and EU and the risk that our product candidates will not
be successfully developed, approved or commercialized. For a
discussion of other risks and uncertainties, and other important
factors, any of which could cause our actual results to differ from
those contained in the forward-looking statements, see the section
entitled “Risk Factors” in our most recent Form 10-K as well as
discussions of potential risks, uncertainties and other important
factors in our subsequent filings with the Securities and Exchange
Commission. All information in this press release is as of the date
of the release, and bluebird bio undertakes no duty to update this
information unless required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191023005806/en/
bluebird bio Investors: Elizabeth Pingpank, 617-914-8736
epingpank@bluebirdbio.com or Media: Jennifer Snyder,
617-448-0281 jsnyder@bluebirdbio.com
bluebird bio (NASDAQ:BLUE)
Historical Stock Chart
From Mar 2024 to Apr 2024
bluebird bio (NASDAQ:BLUE)
Historical Stock Chart
From Apr 2023 to Apr 2024